Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation.
Bakri
S J
SJ
Ekdawi
N S
NS
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006391:Hemangioma / Q000150:complications*; D006801:Humans; D019572:Retinal Neoplasms / Q000150:complications*; D014221:Triamcinolone / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D014221:Triamcinolone; D000068258:Bevacizumab